此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease

2026年8月14日 更新者:Singapore General Hospital

Assessment of Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease

Idiopathic inflammatory myopathies (IIM) are a group of autoimmune conditions characterized by inflammation of muscles with possible extra-muscular manifestations which can include skin and interstitial lung disease (ILD). IIM-associated ILD carries poor prognosis. Particular subtypes of IIM such as anti-melanoma differentiation-associated protein 5 positive (anti-MDA5+) dermatomyositis with ILD are most commonly associated with rapidly progressive-interstitial lung disease (RP-ILD). RP-ILD is defined as worsening dyspnoea on exertion, hypoxaemia, and presence of newly emerging or expanding ground glass opacities on radiographic or computed topography of chest imaging excluding drug or infectious cause. Particularly, patients with anti-MDA5+ dermatomyositis often have RP-ILD with high mortality of over 60% in the first six months of diagnosis. The mainstay of treatment is immunosuppression though there has been no highly efficacious therapy proven to date. Therefore, the overall goal is to improve patient outcomes in IIM-associated RP-ILD including those with anti-MDA5+ dermatomyositis through the development of better treatment regimens. The objective of this research study is to evaluate the efficacy and safety of a combined immunosuppressive regime in patients with IIM-associated RP-ILD. The investigators hypothesize that the simultaneous inhibition of particular targets in the innate and adaptive immune system will improve efficacy and patient survival. The approach involves a combination of four immunosuppressive medications targeting different pathways implicated in IIM associated ILD. If successful, this study could contribute significantly to improving clinical outcomes for patients with IIM-associated RP-ILD.

研究概览

地位

招聘中

详细说明

The primary feature of idiopathic inflammatory myopathies (IIM) is inflammation of muscles, yet extra-muscular manifestations are common such as interstitial lung disease (ILD). Based on both muscular and extra-muscular features, patients can fall into different types of IIMs, including broad subtypes of dermatomyositis (DM), polymyositis (PM), inclusion-body myositis (IBM) and immune-mediating necrotizing myopathies (IMNM). Particular subtypes such as dermatomyositis patients positive for anti-melanoma differentiation-associated protein 5 (anti-MDA5) are most commonly associated with rapidly progressive lung involvement and high mortality, with survival at 1 year being less than 60% despite current available treatment. Treatment for IIM patients involves immunosuppression, though there is no consensus or treatment guidelines available for different subtypes, particularly for myositis-associated RP-ILD. Despite several trials having shown increased efficacy with more aggressive immunosuppressive regimes, mortality still remains high. There is thus an unmet need with regards to treatment of patients with IIM, particularly for myositis-associated RP-ILD.

There is an urgent need to improve outcomes in myositis-associated RP-ILD. Till date, there are no randomised controlled trials that investigate therapy of myositis-associated RP-ILD likely due to the low incidence of the disease. Current best level of evidence for therapies come from single-arm prospective cohort studies with comparison with historical controls. Recent studies using combination therapy to target different aspects of these pathological processes have demonstrated increased efficacy compared to single target alone. This shows that appropriate selection of targets with subsequent combination blockade will be beneficial in treatment of patients with myositis associated RP-ILD. Hence, the investigators propose the utilization of rituximab to block the B-cell involvement, tacrolimus to target T-cells, tofacitinib to block interferon signaling with steroids due to their effects on both the innate and adaptive system in the treatment of myositis-associated RP-ILD. Such combination therapy allows precise targeting of pathways responsible for pathophysiology of the disease, without high individual dosages and hence reducing potential side effects. Till date there are no prospective studies that look into current combination of steroids, tacrolimus, tofacitinib and rituximab in the patients with myositis-associated RP-ILD. However, a drawback for increased immunosuppression is infection, particularly with cytomegalovirus (CMV). The investigators will employ a prophylactic treatment strategy to mitigate the risk of increased infection following higher intensity immunosuppression.

The primary end point will be survival rate at 6 months from initiation of treatment.

Secondary end points include improvement of clinical status, biochemical markers, radiological appearance and parameters on lung function test. Secondary end points also include adverse events rate including side effects from treatment and infection rates.

研究类型

观察性的

注册 (估计的)

80

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

Patients currently undergoing treatment with combined immunosuppressive treatment for myositis-associated rapidly progressive interstitial lung disease

描述

Inclusion Criteria:

  1. Age of 21 years or above;
  2. Diagnosis of myositis associated rapidly progressive interstitial lung disease

Exclusion Criteria:

  1. Age of less than 21 year old;

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Treatment group
Patients with immune-mediated myositis-associated rapidly progressive interstitial lung disease undergoing treatment with combined immunosuppressive treatment
Combination treatment regimen lasting 6 months with A) Steroids: Starting with Intravenous methylprednisolone (500mg once daily for three days) followed by tapering dose of prednisolone B) Rituximab (1000mg given at the start of treatment and 1000mg 2 weeks after the first dose) C) Tacrolimus D) Tofacitinib
其他名称:
  • 利妥昔单抗
  • 泼尼松龙
  • 他克莫司
  • 托法替尼

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
All-cause mortality at 6 months from treatment initiation
大体时间:6 months
Proportion of total participants who demise from all cause till 6 months from treatment initiation (percentage of all participants)
6 months

次要结果测量

结果测量
措施说明
大体时间
Change in clinical status through Modified Medical Research Council Dyspnea Scale
大体时间:6 months
The Modified Medical Research Council (mMRC) Dyspnea Scale will be used to rate participants' functional status at start of treatment and at 6 months post treatment (0 to 4).
6 months
Change in clinical status through requirement of supplemental oxygen at 6 months
大体时间:6 months
Proportion of participants who require oxygen supplementation at the start of treatment and 6 months post treatment (percentage of all participants).
6 months
Safety of treatment regimen in participants
大体时间:6 months
Number of adverse infection events experienced by participants
6 months
Safety of treatment regimen in participants
大体时间:6 months
Number of adverse haematological events leading to change of medication as per managing physician
6 months
Safety of treatment regimen in participants
大体时间:6 months
Number of adverse biochemical events leading to change of medication as per managing physician
6 months
Change in biochemical markers of disease activity
大体时间:1 year
Levels of C-reactive protein (mg/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year
1 year
Change in biochemical markers of disease activity
大体时间:1 year
Levels of Erythrocyte sedimentation rate (mm/h) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
1 year
Change in biochemical markers of disease activity
大体时间:1 year
Levels of Ferritin (ug/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
1 year
Change in biochemical markers of disease activity
大体时间:1 year
Levels of Lactate dehydrogenase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
1 year
Change in biochemical markers of disease activity
大体时间:1 year
Levels of Creatine kinase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
1 year
Change in biochemical markers of disease activity
大体时间:1 year
Levels of Aldolase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年12月26日

初级完成 (估计的)

2029年7月1日

研究完成 (估计的)

2029年7月1日

研究注册日期

首次提交

2026年4月23日

首先提交符合 QC 标准的

2026年8月14日

首次发布 (实际的)

2026年8月20日

研究记录更新

最后更新发布 (实际的)

2026年8月20日

上次提交的符合 QC 标准的更新

2026年8月14日

最后验证

2025年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅